Citadel Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Citadel Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-328,700	Closed	-$17.3M	–	14833
2026 Q1	$17.3M	Buy	328,700 +235,000	+251%	+$9.65M	﹤0.01%	2502
2025 Q4	$3.79M	Buy	93,700 +79,500	+560%	+$1.84M	﹤0.01%	4760
2025 Q3	$107K	Sell	14,200 -75,300	-84%	-$481K	﹤0.01%	11804
2025 Q2	$334K	Sell	89,500 -43,100	-33%	-$135K	﹤0.01%	9551
2025 Q1	$366K	Buy	132,600 +57,000	+75%	+$233K	﹤0.01%	9146
2024 Q4	$419K	Sell	75,600 -155,100	-67%	-$1.05M	﹤0.01%	8956
2024 Q3	$1.92M	Buy	230,700 +205,300	+808%	+$1.69M	﹤0.01%	5615
2024 Q2	$173K	Buy	25,400 +6,200	+32%	+$37.6K	﹤0.01%	10142
2024 Q1	$126K	Buy	19,200 +4,900	+34%	+$32K	﹤0.01%	11044
2023 Q4	$92.8K	Buy	14,300 +400	+3%	+$2.12K	﹤0.01%	11028
2023 Q3	$69.9K	Sell	13,900 -12,100	-47%	-$76.8K	﹤0.01%	11329
2023 Q2	$228K	Buy	+26,000	New	+$303K	﹤0.01%	9602

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's TERN Position: Q2 2026 in Review

Citadel Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 3,218,810 shares — an estimated $170M sold.

Citadel Advisors first reported a position in TERN in Q1 2021 and held it in 17 quarters. The position peaked at $170M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Citadel Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 3,218,810 Terns Pharmaceuticals shares in Q2 2026, an estimated $170M.
Citadel Advisors first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 17 quarters.
Citadel Advisors's Terns Pharmaceuticals position peaked at $170M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.